Literature DB >> 33466521

Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Patients with Liver Cirrhosis.

Wen-Chi Chen1, Chih-Hsin Hung2, Yao-Shen Chen3, Jin-Shiung Cheng1, Susan Shin-Jung Lee3, Fan-Chen Tseng4, Ming-Fang Cheng2,5,6,7, Jiun-Ling Wang8,9.   

Abstract

BACKGROUND: This study aimed to investigate the frequency of sequence type (ST) 131 strains and outcome of cirrhotic patients with bloodstream infections (BSIs) caused by extended-spectrum beta-lactamase-producing Escherichia coli (ESBLEC) and non-extended-spectrum beta-lactamase-producing Escherichia coli (NESBLEC).
METHODS: The incidence of ST 131 strains, hospital stay, and 30-day re-admission/mortality were compared between 51 ESBLEC and 51 NESBLEC bacteremic patients with cirrhosis.
RESULTS: ST 131 strains were found in 35.3% of the ESBLEC group and 0% of the NESBLEC group (p < 0.001). Mean hospital stay was 26.5 days in the ESBLEC group and 17.1 days in the NESBLEC group (p = 0.006). Thirty-day re-admission rates were 11.8% in the ESBLEC group and 5.9% in the NESBLEC group (p = 0.5). ST 131 strains were associated with 30-day re-admission (odds ratio: 4.5, 95% confidence interval: 1.1-18.9). Thirty-day mortality rate was 31.4% in the ESBLEC group and 23.5% in the NESBLEC group (p = 0.4).
CONCLUSION: In patients with cirrhosis, the ESBLEC BSIs group had a higher frequency of ST 131 strains and longer hospital stay than the NESBLEC BSIs group with similar 30-day re-admission/mortality. ST 131 strains were associated with 30-day re-admission.

Entities:  

Keywords:  Escherichia coli; bacteremia cirrhosis; extended-spectrum beta-lactamase; sequence type 131

Year:  2021        PMID: 33466521      PMCID: PMC7824895          DOI: 10.3390/pathogens10010037

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  42 in total

Review 1.  Bacterial infections in end-stage liver disease: current challenges and future directions.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Patrick S Kamath
Journal:  Gut       Date:  2012-06-03       Impact factor: 23.059

Review 2.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

3.  Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.

Authors:  A Courpon-Claudinon; A Lefort; X Panhard; O Clermont; Q Dornic; B Fantin; F Mentré; M Wolff; E Denamur; C Branger
Journal:  Clin Microbiol Infect       Date:  2011-04       Impact factor: 8.067

4.  CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.

Authors:  Teresa C Horan; Mary Andrus; Margaret A Dudeck
Journal:  Am J Infect Control       Date:  2008-06       Impact factor: 2.918

5.  Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Un-In Wu; Ching-Shiang Yang; Wan-Chin Chen; Yee-Chun Chen; Shan-Chwen Chang
Journal:  J Microbiol Immunol Infect       Date:  2010-08       Impact factor: 4.399

6.  Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan.

Authors:  Ju-Hsin Chia; Chishih Chu; Lin-Hui Su; Cheng-Hsun Chiu; An-Jing Kuo; Chien-Feng Sun; Tsu-Lan Wu
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.

Authors:  Jesús Rodríguez-Baño; Encarnación Picón; Paloma Gijón; José Ramón Hernández; Maite Ruíz; Carmen Peña; Manuel Almela; Benito Almirante; Fabio Grill; Javier Colomina; Monserrat Giménez; Antonio Oliver; Juan Pablo Horcajada; Gemma Navarro; Ana Coloma; Alvaro Pascual
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

8.  Multiresistant bacterial infections in liver cirrhosis: Clinical impact and new empirical antibiotic treatment policies.

Authors:  Juan Acevedo
Journal:  World J Hepatol       Date:  2015-05-08

9.  Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15.

Authors:  Marie-Hélène Nicolas-Chanoine; Jorge Blanco; Véronique Leflon-Guibout; Raphael Demarty; Maria Pilar Alonso; Maria Manuela Caniça; Yeon-Joon Park; Jean-Philippe Lavigne; Johann Pitout; James R Johnson
Journal:  J Antimicrob Chemother       Date:  2007-12-11       Impact factor: 5.790

10.  Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection.

Authors:  Yangxin Xie; Bo Tu; Xin Zhang; Jingfeng Bi; Lei Shi; Peng Zhao; Weiwei Chen; Suxia Liu; Dongping Xu; Enqiang Qin
Journal:  Oncotarget       Date:  2017-12-22
View more
  1 in total

1.  Escherichia/Shigella, SCFAs, and Metabolic Pathways-The Triad That Orchestrates Intestinal Dysbiosis in Patients with Decompensated Alcoholic Cirrhosis from Western Mexico.

Authors:  Tonatiuh Abimael Baltazar-Díaz; Luz Alicia González-Hernández; Juan Manuel Aldana-Ledesma; Marcela Peña-Rodríguez; Alejandra Natali Vega-Magaña; Adelaida Sara Minia Zepeda-Morales; Rocío Ivette López-Roa; Susana Del Toro-Arreola; Erika Martínez-López; Adriana María Salazar-Montes; Miriam Ruth Bueno-Topete
Journal:  Microorganisms       Date:  2022-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.